Sunitinib-induced hemoglobin changes are related to the dosing schedule.
van der Veldt
Astrid A M
AA
Boven
Epie
E
Vroling
Laura
L
Broxterman
Henk J
HJ
van den Eertwegh
Alfons J M
AJ
Haanen
John G
JG
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004334:Drug Administration Schedule; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D011086:Polycythemia / Q000139:chemically induced; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D000077210:Sunitinib; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors / Q000502:physiology
D000970:Antineoplastic Agents; D006454:Hemoglobins; D007211:Indoles; D011758:Pyrroles; D040301:Vascular Endothelial Growth Factor Receptor-2; D000077210:Sunitinib